基于病情严重程度的COVID-19患者SARS-COV-2抗体反应

Fenty Fenty, I. Putra
{"title":"基于病情严重程度的COVID-19患者SARS-COV-2抗体反应","authors":"Fenty Fenty, I. Putra","doi":"10.24293/ijcpml.v29i1.1951","DOIUrl":null,"url":null,"abstract":"Any individual infected by COVID-19 can suffer various degrees of disease such as asymptomatic symptoms, mild, moderate or severe. Response to the antibody formation in the human body can be affected by the severity of COVID-19. Many researchers have stated that patients suffering a severe COVID-19 had a more significant antibody response, proven by higher antibody titers than those suffering mild or moderate severity. This research aimed to observe the different antibody responses in COVID-19 patients based on the severity of the disease. The research was a retrospective study with a cross-sectional design. The inclusion criteria were confirmed SARS-COV-2 patients determined by RT-PCR test results with age ≥18 years old and a complete medical record taken from electronic medical records and Laboratory Information System (LIS). This study involved 100 COVID-19 patients consisting of 51% non-severe and 49% severe COVID-19. Patients in the non-severe group had a relatively lower IgM and IgG antibody response than patients in the severe group. It could be th primarily observed at the time of antibody measurement > 15 day of symptoms onset (p<0.05).","PeriodicalId":354500,"journal":{"name":"Indonesian Journal of Clinical Pathology and Medical Laboratory","volume":"2005 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Antibody Responses to SARS-COV-2 of COVID-19 Patients Based on the Disease Severity\",\"authors\":\"Fenty Fenty, I. Putra\",\"doi\":\"10.24293/ijcpml.v29i1.1951\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Any individual infected by COVID-19 can suffer various degrees of disease such as asymptomatic symptoms, mild, moderate or severe. Response to the antibody formation in the human body can be affected by the severity of COVID-19. Many researchers have stated that patients suffering a severe COVID-19 had a more significant antibody response, proven by higher antibody titers than those suffering mild or moderate severity. This research aimed to observe the different antibody responses in COVID-19 patients based on the severity of the disease. The research was a retrospective study with a cross-sectional design. The inclusion criteria were confirmed SARS-COV-2 patients determined by RT-PCR test results with age ≥18 years old and a complete medical record taken from electronic medical records and Laboratory Information System (LIS). This study involved 100 COVID-19 patients consisting of 51% non-severe and 49% severe COVID-19. Patients in the non-severe group had a relatively lower IgM and IgG antibody response than patients in the severe group. It could be th primarily observed at the time of antibody measurement > 15 day of symptoms onset (p<0.05).\",\"PeriodicalId\":354500,\"journal\":{\"name\":\"Indonesian Journal of Clinical Pathology and Medical Laboratory\",\"volume\":\"2005 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indonesian Journal of Clinical Pathology and Medical Laboratory\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24293/ijcpml.v29i1.1951\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Clinical Pathology and Medical Laboratory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24293/ijcpml.v29i1.1951","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

任何感染COVID-19的人都可能出现无症状、轻度、中度和重度等不同程度的疾病。人体对抗体形成的反应可能受到COVID-19严重程度的影响。许多研究人员表示,严重的COVID-19患者的抗体反应更明显,抗体滴度高于轻度或中度严重的患者。本研究旨在观察COVID-19患者根据疾病严重程度的不同抗体反应。本研究为横断面设计的回顾性研究。纳入标准为年龄在‰~ 18岁之间,从电子病历和实验室信息系统(LIS)中获取完整病历的经RT-PCR检测结果确诊的SARS-COV-2患者。该研究涉及100名COVID-19患者,其中51%为非重症,49%为重症。非重症组患者IgM和IgG抗体应答较重症组低。在出现症状后> 15天进行抗体检测时可主要观察到(p<0.05)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antibody Responses to SARS-COV-2 of COVID-19 Patients Based on the Disease Severity
Any individual infected by COVID-19 can suffer various degrees of disease such as asymptomatic symptoms, mild, moderate or severe. Response to the antibody formation in the human body can be affected by the severity of COVID-19. Many researchers have stated that patients suffering a severe COVID-19 had a more significant antibody response, proven by higher antibody titers than those suffering mild or moderate severity. This research aimed to observe the different antibody responses in COVID-19 patients based on the severity of the disease. The research was a retrospective study with a cross-sectional design. The inclusion criteria were confirmed SARS-COV-2 patients determined by RT-PCR test results with age ≥18 years old and a complete medical record taken from electronic medical records and Laboratory Information System (LIS). This study involved 100 COVID-19 patients consisting of 51% non-severe and 49% severe COVID-19. Patients in the non-severe group had a relatively lower IgM and IgG antibody response than patients in the severe group. It could be th primarily observed at the time of antibody measurement > 15 day of symptoms onset (p<0.05).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信